Between the Lines

Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

PET/CT–Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

PET/CT–Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

September 13th 2021

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, provide insight on the results and clinical implications of the EMPIRE-1 trial in prostate cancer.

Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors

Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors

August 24th 2021

In this program, George Ansstas, MD, and Firas B. Badin, MD, discuss a recently published paper on ctDNA for analysis of immunotherapy efficacy in individual patients with solid tumor malignancies.

Thoracic Oncologist Specialists

Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions

August 20th 2021

In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.

Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box

Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box

August 9th 2021

In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.

<12